Previous 10 | Next 10 |
Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer PR Newswire CAMBRIDGE, Mass. , March 30, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the pot...
Evelo Biosciences (EVLO) and Abdul Latif Jameel Health have entered into a strategic collaboration to develop and commercialize Evelo’s lead inflammation product candidate EDP1815 in the Middle East, Turkey, and Africa.The Company is also conducting a Phase 2 trial for EDP1815 in psori...
-- Collaboration expected to accelerate access to Evelo’s lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Health’s first biotechnolog...
Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q4 2020 Earnings Call Mar 09, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q4 2020 Earnings Call Transcript
Evelo Biosciences, Inc. (EVLO) Q4 2020 Results Earnings Conference Call March 09, 2021, 08:30 AM ET Company Participants Jessica Cotrone - VP & Head, Communications Balkrishan Gill - President, CEO, Treasurer, Principal Financial Officer & Director Mark Bodmer - Chief Scientific Offic...
The following slide deck was published by Evelo Biosciences, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Evelo Biosciences, Inc. 2020 Q4 - Results - Earnings Call Presentation
–Announced new positive data in human experimental model of inflammation of EDP1815– –Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021– –Initiated Phase 1b clinical tria...
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, March 9, 202...
4D Pharma (DDDD.l) (FRPRF) is an under covered UK domiciled company working in the microbiome space. The company will be NASDAQ listed in Q1 of 2021. 4D Pharma seeks to understand the functions of bacteria in order to harness these functions to treat disease. 4D Pharma has produce...
CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced the appointment of John Hohneker, M.D., to its Board of Directors. “John is...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...